Drug – bio-affecting and body treating compositions – Lymphokine – Interleukin
Patent
1988-11-16
1989-09-05
Brown, Johnnie R.
Drug, bio-affecting and body treating compositions
Lymphokine
Interleukin
514 8, 514 2, 435 68, A61K 3702
Patent
active
048637270
ABSTRACT:
Anti-tumor activity in mammals can be augmented by administering to the mammalian host a synergistically effective amount of TNF and IL-2 or of TNF and IFN-.beta., or of TNF, IL-2 and IFN-.beta. in combination. The composition of TNF and IL-2 and/or IFN-.beta. may be prepared in vitro or administered separately to the host. If the TNF and IL-2 are administered sequentially, the TNF must be administered prior to the IL-2 to obtain synergy. The composition is useful for treating such cancers as mastocytoma, melanoma, leukemia, lymphoma, mammary adenocarcinoma, and pharyngeal squamous cell carcinoma.
REFERENCES:
patent: 4518584 (1985-05-01), Mark et al.
patent: 4604377 (1986-08-01), Fernandes et al.
patent: 4650674 (1987-03-01), Aggarwal et al.
patent: 4677063 (1987-06-01), Mark et al.
patent: 4677064 (1987-06-01), Mark et al.
patent: 4677197 (1987-06-01), Lin et al.
Winkelhake et al/Cancer Res (1987), 47:3948-53.
Nishimura et al/Int J. Cancer (1987), 40:255-61.
Owen-Schaub et al/Cancer Res (1988), 48:788-92.
Zimmerman et al, "Sequence Dependence of Murine Tumor Therapy with Human Recombinant Tumor Necrosis Factor and Interleukin-2".
Svedersky et al., J. Immunol., 133:714-718 (1984).
Shalaby et al., J. Interferon Res., 5:571-581 (1985).
Dempsey et al., J. Immunol., 129:2514-2510 (1982).
Svedersky et al., "Enhanced Antitumor Activity of Recombinant IFN-Gamma in Combination with TNFs and Chemothereapeutic Agents", Abstracts of Third Int'l Conference on Immuno-Pharmacology, Florence, Italy, May 6-9, 1985, Pergamon Press, p. 330 of Int'l J. of Immunopharamcology, 7, Pergamon Press, ed. Mullen, 1985.
Second Quarter Report-Dec. 31, 1985 of Cetus Corporation.
Wedbush Noble, Cooke, Inc., Report of 9/30/85, Issue No. 1 (p. 2).
Williams et al., J. Immunol., 130:518-520 (1983).
Matsunoga et al. Cancer Lett., 20:21-28 (1983).
Papermaster et al., Human Lymphokines, Kahn et al., ed., pp. 459-477 (Jun. 30, 1982).
Matthews et al., British J. Cancer (1979), 40, 534.
Buessow et al., Leukemia Research, 8:801-811 (1984).
Nishimura et al., Int. J. Cancer 40: 255-261 (1987).
Winkelhake et al., Cancer Research, 47: 3948-3953 (1987).
Kolitz et al., Arz-Forsch/Drug Res., 35(11), No. 10 (1985), pp. 1607-1615.
Williamson et al, PNAS USA, vol. 80; Sep. 1983, pp. 5397-5401.
Higashi et al, cited in Chem. Abstracts, vol. 99:134710j, 1983.
Nedwin et al, J. Immunol., vol. 135, No. 4, Oct. 1958, pp. 2492-2497.
Mier et al, J. Immunol., vol. 128, No. 3, Mar. 1982, pp. 1122-1127.
Winkelhake Jeffrey L.
Zimmerman Robert
Brown Johnnie R.
Cetus Corporation
Giotta Gregory J.
Halluin Albert P.
Hasak Janet E.
LandOfFree
Combination therapy using interleukin-2 and tumor necrosis facto does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combination therapy using interleukin-2 and tumor necrosis facto, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combination therapy using interleukin-2 and tumor necrosis facto will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-242383